Kidney Cancer Diagnostics Market: Emerging Economies Expected to Influence Growth until 2022

Posted on 2018-11-16 by Mark Hub in Healthcare // 0 Comments

Fact.MR

Rockville, US, 2018-Nov-16 — /EPR Network/ — Kidney cancer is a type of cancer which starts in kidney cells. Two major types of kidney cancer include transitional cell carcinoma (TCC) and renal cell carcinoma (RCC). Different types of kidney cancer get developed in different ways which imply different long-term outcomes. This cancer originates in two principal locations of the kidney – the renal pelvis and the renal tubule.

A new report published by Fact.MR estimates the global kidney cancer diagnostics market to exhibit an impressive expansion at during the forecast period 2017 to 2022. In terms of revenues, the global market for kidney cancer diagnostics will reach nearly US$ 700 Mn by 2022-end.

Request For Free Sample Report @ https://www.factmr.com/connectus/sample?flag=S&rep_id=56

Targeted Systemic Therapies for Metastatic Kidney Cancer are Providing Significant Benefits to Survival and Progression

Over the past few years, the diagnosis and management of kidney cancer, or, renal cell carcinoma (RCC), have undergone tremendous transformations. A number of discoveries, studies, and trails are being taken in renal mass biopsy, minimally-invasive thermal ablation, and active surveillance, owing to the surge in diagnosis rate of small renal masses, usually in patients with high morbidity risks related to operative treatment. In addition, targeted systemic therapies associated with metastatic kidney cancer have replaced cytokine-based treatment, providing significant benefits to survival and progression. Recent trails and reviews have cemented the partial nephrectomy’s role as the standard diagnosis-based surgical management option for majority of low-stage masses, and roles of adrenalectomy and lymphadenectomy pertaining to nephrectomy. These incidences are estimated to augment growth of the global kidney cancer diagnostics market.

Kidney cancer has been witnessed to occur majorly in older population. Diagnosis of kidney cancer becomes an intricate task, considering the condition of geriatric patients. While staple diagnostic technologies such as MRI and CT scan continue to play a pivotal role in the global market, patients are also expecting the emergence of all-inclusive diagnosis tests. Medical organizations are also funneling high investments in R&D of kidney cancer diagnostics, particularly to improve the precision of early stage diagnosis tests. Through advancements in medical technology, the global market for kidney cancer diagnostics is also expected to witness emergence of new tests that can simultaneously decelerate the pace of tumor maturation between multiple stages of kidney cancer.

9 Estimations from Fact.MR’s Report on the Global Kidney Cancer Diagnostics Market

Based on end-users, the hospital-associated labs will remain preferred in the market for kidney cancer diagnostics, and are expected to account for the largest revenues over the forecast period.
Independent diagnostic laboratories are estimated to remain the second largest end-users in the global market for kidney cancer diagnostics.
Cancer research institutes will register the fastest expansion in the market during the forecast period.
Immunochemistry tests will remain sought-after in the market for kidney cancer diagnostics, and revenues from these tests will account for US$ 351.8 Mn by 2022-end. Among test type, Immunochemistry test is expected to exhibit the highest CAGR through 2022, followed by the complete blood count test.
Urine analysis is anticipated to remain the second most lucrative tests for diagnosis of kidney cancer across the globe.
Revenues from blood chemistry tests related to kidney cancer diagnostics are expected to remain comparatively lower in the market over the forecast period.
North America will continue to account for the largest revenues in the kidney cancer diagnostics market, followed by Europe.
Market for kidney cancer diagnostics in Europe will register a relatively higher CAGR than in North America throughout the forecast period.
Asia Pacific excluding Japan (APEJ) is expected to remain the fastest growing market for kidney cancer diagnostics over the forecast period.

View Full Report with Table of Content @ https://www.factmr.com/report/56/kidney-cancer-diagnostics-market

Competition Tracking

The report has also profiled leading players in the global market for kidney cancer diagnostics, which include NeoGenomics Laboratories, Myriad Genetics Inc, NanoString Technologies Inc., Rosetta Genomics, Sysmex Corporation, Illumina, Inc., Roche Holding AG, Quest Diagnostics Incorporated, Thermo Fisher Scientific Inc., and Abbott Laboratories.

Hospital-associated Labs will Remain Preferred for Kidney Cancer Diagnostics

On the basis of end-users, hospital-associated labs are estimated to remain preferred for kidney cancer diagnostics, accounting for the largest revenues by 2022-end. Independent diagnostic laboratories will continue to be the second most lucrative end-users in the global kidney cancer diagnostics market. In addition, cancer research institutes are expected to register the highest CAGR in the market through 2022.

Immunochemistry tests will continue to be sought-after for kidney cancer diagnostics, with revenues expected to reach US$ 351.8 Mn by 2022-end. This test type segment is projected to register the highest CAGR in the market through 2022, followed by complete blood count test.

Urine analysis will remain the second largest adopted tests for kidney cancer diagnostics across the globe. However, revenues from blood chemistry tests of kidney cancer diagnostics will continue to be lower as compared to rest of the test segments in the market.

North America to Remain the Largest Market for Kidney Cancer Diagnostics

In terms of revenues, North America is expected to remain the largest market for kidney cancer diagnostics, followed by Europe. However, kidney cancer diagnostics market in Europe will exhibit a comparatively higher CAGR than North America during the forecast period. In addition, Asia Pacific excluding Japan (APEJ) will continue to be the fastest expanding market for kidney cancer diagnostics through 2022.

Table of Content:

Chapter 1 Global Kidney Cancer Diagnostics Market – Executive Summary 13

Chapter 2 Global Kidney Cancer Diagnostics Market Overview 15
2.1 Introduction 15
2.1.1 Global Kidney Cancer Diagnostics Market Taxonomy 15
2.1.2 Global Kidney Cancer Diagnostics Market Definition 15
2.2 Global Kidney Cancer Diagnostics Market Size (US$ Mn) and Forecast, 2012-2022 16
2.2.1 Global Kidney Cancer Diagnostics Market Y-o-Y Growth 16
2.3 Global Kidney Cancer Diagnostics Market Dynamics 16
2.3.1 Drivers 16
2.3.2 Restraints 17
2.3.3 Trends 17
2.4 Supply Chain 17
2.5 Epidemiology 17
2.6 List of Distributors 17
2.7 Average Pricing Analysis 18
2.8 Regulations 18
2.9 Key Participants Market Presence (Intensity Map) By Region 18

Chapter 3 Global Kidney Cancer Diagnostics Market Analysis and Forecast By Test Type 19
3.1 Global Kidney Cancer Diagnostics Market Size and Forecast By Test Type, 2012-2022 19
3.1.1 Immunohistochemistry Kidney Cancer Diagnostics Market Size and Forecast, 2012-2022 19
3.1.1.1 Revenue (US$ Mn) Comparison, By Region 19
3.1.1.2 Market Share Comparison, By Region 21
3.1.1.3 Y-o-Y growth Comparison, By Region 21
3.1.2 Urine Analysis Kidney Cancer Diagnostics Market Size and Forecast, 2012-2022 22
3.1.2.1 Revenue (US$ Mn) Comparison, By Region 22
3.1.2.2 Market Share Comparison, By Region 24
3.1.2.3 Y-o-Y growth Comparison, By Region 24
3.1.3 Complete Blood Count Kidney Cancer Diagnostics Market Size and Forecast, 2012-2022 25

Continued……………..

Grow Your Business From Expert Advice @ https://www.factmr.com/connectus/sample?flag=AE&rep_id=56

About FactMR
FactMR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market Insights reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that’s why we publish multi-industry global, regional, and country-specific research reports.

Matched content

Editor’s pick